<DOC>
	<DOCNO>NCT00460850</DOCNO>
	<brief_summary>This single arm study evaluate efficacy safety PEGASYS patient lamivudine resistant HBeAg negative chronic hepatitis B . Patients receive PEGASYS 180 microgram s.c. weekly 48 week ; follow , 48 week period treatment-free follow-up . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>adult patient , 1865 year age ; HBeAg negative chronic hepatitis B ; treat lamivudine &gt; =6 month ; demonstrate lamivudine resistance ; compensate liver disease . severe hepatic dysfunction ; previous treatment antiviral lamivudine ; immunosuppressant treatment past 6 month ; coinfection hepatitis A , C , D virus human immunodeficiency virus ; medical condition associate chronic liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>